Comerica Bank trimmed its position in Repligen Corporation (NASDAQ:RGEN) by 4.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,739 shares of the biotechnology company’s stock after selling 1,724 shares during the period. Comerica Bank owned approximately 0.10% of Repligen Corporation worth $1,527,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in RGEN. Ameritas Investment Partners Inc. acquired a new stake in shares of Repligen Corporation in the 1st quarter valued at approximately $103,000. Victory Capital Management Inc. raised its position in shares of Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 1,475 shares during the period. JPMorgan Chase & Co. raised its position in shares of Repligen Corporation by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 908 shares during the period. US Bancorp DE raised its position in shares of Repligen Corporation by 1.2% in the 2nd quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 54 shares during the period. Finally, Benin Management CORP acquired a new stake in shares of Repligen Corporation in the 2nd quarter valued at approximately $207,000. Institutional investors and hedge funds own 97.91% of the company’s stock.

WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/14/comerica-bank-has-1-53-million-position-in-repligen-corporation-rgen.html.

A number of analysts recently weighed in on RGEN shares. Janney Montgomery Scott increased their price target on shares of Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. BidaskClub upgraded shares of Repligen Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. William Blair started coverage on shares of Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating on the stock. Jefferies Group LLC restated a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Finally, Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Wednesday, June 14th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $42.00.

Shares of Repligen Corporation (NASDAQ RGEN) opened at 43.00 on Thursday. The firm’s 50-day moving average is $41.85 and its 200 day moving average is $38.55. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The firm has a market capitalization of $1.61 billion, a P/E ratio of 84.15 and a beta of 1.21.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 EPS. Equities research analysts predict that Repligen Corporation will post $0.59 earnings per share for the current year.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.